Recent Analysts’ Ratings Updates for Portola Pharmaceuticals (PTLA)

Several brokerages have updated their recommendations and price targets on shares of Portola Pharmaceuticals (NASDAQ: PTLA) in the last few weeks:

  • 11/9/2018 – Portola Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. “
  • 11/8/2018 – Portola Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 11/8/2018 – Portola Pharmaceuticals was given a new $30.00 price target on by analysts at Credit Suisse Group AG. They now have a “hold” rating on the stock.
  • 11/8/2018 – Portola Pharmaceuticals was given a new $30.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 10/11/2018 – Portola Pharmaceuticals had its price target lowered by analysts at Morgan Stanley from $34.00 to $32.00. They now have an “equal weight” rating on the stock.
  • 10/11/2018 – Portola Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $27.00 price target on the stock. According to Zacks, “Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. “
  • 10/6/2018 – Portola Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 9/26/2018 – Portola Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 9/20/2018 – Portola Pharmaceuticals was given a new $60.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 9/12/2018 – Portola Pharmaceuticals had its “buy” rating reaffirmed by analysts at William Blair.
  • 9/10/2018 – Portola Pharmaceuticals was given a new $60.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.

Portola Pharmaceuticals stock traded down $0.60 during mid-day trading on Friday, reaching $22.54. 391,159 shares of the company traded hands, compared to its average volume of 1,482,546. The company has a current ratio of 6.69, a quick ratio of 6.59 and a debt-to-equity ratio of 0.91. Portola Pharmaceuticals Inc has a fifty-two week low of $18.18 and a fifty-two week high of $56.70. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -4.69 and a beta of 2.04.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.54) by $0.46. Portola Pharmaceuticals had a negative net margin of 1,503.29% and a negative return on equity of 111.64%. The business had revenue of $14.20 million for the quarter, compared to analyst estimates of $7.10 million. During the same quarter in the prior year, the business posted ($1.41) EPS. Portola Pharmaceuticals’s revenue for the quarter was up 270.8% compared to the same quarter last year. On average, sell-side analysts predict that Portola Pharmaceuticals Inc will post -5.85 EPS for the current fiscal year.

In other Portola Pharmaceuticals news, Director Jeffrey W. Bird acquired 390,000 shares of the business’s stock in a transaction dated Thursday, August 23rd. The shares were purchased at an average price of $25.84 per share, for a total transaction of $10,077,600.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey W. Bird acquired 137,563 shares of the business’s stock in a transaction dated Tuesday, August 21st. The stock was acquired at an average price of $25.17 per share, for a total transaction of $3,462,460.71. The disclosure for this purchase can be found here. 4.60% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the company. SeaCrest Wealth Management LLC purchased a new stake in Portola Pharmaceuticals during the second quarter worth $191,000. BB&T Securities LLC purchased a new stake in Portola Pharmaceuticals during the second quarter worth $201,000. Oppenheimer Asset Management Inc. purchased a new stake in Portola Pharmaceuticals during the second quarter worth $230,000. Quantitative Systematic Strategies LLC purchased a new stake in Portola Pharmaceuticals during the second quarter worth $234,000. Finally, Smith Asset Management Group LP boosted its holdings in Portola Pharmaceuticals by 51.1% during the third quarter. Smith Asset Management Group LP now owns 8,100 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 2,740 shares in the last quarter. Hedge funds and other institutional investors own 94.47% of the company’s stock.

Portola Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. The company's two FDA-approved medicines are Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness.

Read More: Should You Consider an Index Fund?

Receive News & Ratings for Portola Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply